Broadwood Capital Inc bought $3.9M of Oncocyte (OCX)

Executed Oct 2 2024, disclosed Oct 4 2024, 2 days later.

Value, as filed

$3.9M

1,315,339 sh × $2.95

Executed

Oct 2 2024

the trade date, as filed

Disclosed

Oct 4 2024

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

not yet measured

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

The filer

BI Broadwood Capital Inc 10% owner profile →

Broadwood Capital Inc (10% owner) filed 6 Form 4 reports as a reporting entity in the past 24 months (6 purchases, 0 sales), most often in STAA. Across 5 priced purchase filings, the average 21-session return was -1.2% from execution and -4.5% from disclosure (delay-adjusted; derived). The largest single filing was $11.2M of STAA (661,961 sh across 5 lots, as filed), executed Feb 27 2025.

The name

OCX OCX OCX · 5 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→